Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

Stefan Kostense; Wouter Koudstaal; Mieke Sprangers; Gerrit Jan Weverling; Germaine Penders; Niels Helmus; Ronald Vogels; Margreet Bakker; Ben Berkhout; Menzo Havenga; Jaap Goudsmit

doi:https://doi.org/10.1097/00002030-200405210-00019

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

Stefan Kostense, Wouter Koudstaal, Mieke Sprangers, Gerrit Jan Weverling, Germaine Penders, Niels Helmus, Ronald Vogels, Margreet Bakker, Ben Berkhout, Menzo Havenga, Jaap Goudsmit

Research output: Contribution to journal › Article › Academic › peer-review

149 Citations (Scopus)

Abstract

The seroprevalence of adenovirus types 5 (Ad5) and 35 (Ad35) was investigated in patients at risk of AIDS. The seroprevalence of Ad5 was higher than Ad35 in HIV-infected patients from the Netherlands (60% versus 7%) and sub-Saharan Africa (90% versus 20%). The seroprevalence was similar among HIV-infected and uninfected individuals, and remained constant during progression to AIDS. Ad35 is less prone to neutralization than Ad5, encouraging the further development of Ad35 for vaccination against HIV

Original language	English
Pages (from-to)	1213-1216
Journal	AIDS (London, England)
Volume	18
Issue number	8
DOIs	https://doi.org/10.1097/00002030-200405210-00019
Publication status	Published - 2004

Access to Document

https://doi.org/10.1097/00002030-200405210-00019

Cite this

@article{67cd682a3b28448d8aa48b20595ad859,

title = "Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector",

abstract = "The seroprevalence of adenovirus types 5 (Ad5) and 35 (Ad35) was investigated in patients at risk of AIDS. The seroprevalence of Ad5 was higher than Ad35 in HIV-infected patients from the Netherlands (60% versus 7%) and sub-Saharan Africa (90% versus 20%). The seroprevalence was similar among HIV-infected and uninfected individuals, and remained constant during progression to AIDS. Ad35 is less prone to neutralization than Ad5, encouraging the further development of Ad35 for vaccination against HIV",

author = "Stefan Kostense and Wouter Koudstaal and Mieke Sprangers and Weverling, {Gerrit Jan} and Germaine Penders and Niels Helmus and Ronald Vogels and Margreet Bakker and Ben Berkhout and Menzo Havenga and Jaap Goudsmit",

year = "2004",

doi = "https://doi.org/10.1097/00002030-200405210-00019",

language = "English",

volume = "18",

pages = "1213--1216",

journal = "AIDS (London, England)",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

TY - JOUR

T1 - Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

AU - Kostense, Stefan

AU - Koudstaal, Wouter

AU - Sprangers, Mieke

AU - Weverling, Gerrit Jan

AU - Penders, Germaine

AU - Helmus, Niels

AU - Vogels, Ronald

AU - Bakker, Margreet

AU - Berkhout, Ben

AU - Havenga, Menzo

AU - Goudsmit, Jaap

PY - 2004

Y1 - 2004

N2 - The seroprevalence of adenovirus types 5 (Ad5) and 35 (Ad35) was investigated in patients at risk of AIDS. The seroprevalence of Ad5 was higher than Ad35 in HIV-infected patients from the Netherlands (60% versus 7%) and sub-Saharan Africa (90% versus 20%). The seroprevalence was similar among HIV-infected and uninfected individuals, and remained constant during progression to AIDS. Ad35 is less prone to neutralization than Ad5, encouraging the further development of Ad35 for vaccination against HIV

AB - The seroprevalence of adenovirus types 5 (Ad5) and 35 (Ad35) was investigated in patients at risk of AIDS. The seroprevalence of Ad5 was higher than Ad35 in HIV-infected patients from the Netherlands (60% versus 7%) and sub-Saharan Africa (90% versus 20%). The seroprevalence was similar among HIV-infected and uninfected individuals, and remained constant during progression to AIDS. Ad35 is less prone to neutralization than Ad5, encouraging the further development of Ad35 for vaccination against HIV

U2 - https://doi.org/10.1097/00002030-200405210-00019

DO - https://doi.org/10.1097/00002030-200405210-00019

M3 - Article

C2 - 15166541

SN - 0269-9370

VL - 18

SP - 1213

EP - 1216

JO - AIDS (London, England)

JF - AIDS (London, England)

IS - 8

ER -